Can-Fite BioPharma Ltd. Financials
Can-Fite BioPharma Ltd. (CANF) reported $405K in revenue for fiscal year 2025, down 39.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Can-Fite BioPharma is still operating like a capital-funded research vehicle, with financing—not customers—supporting day-to-day activity.
Over the last three years, revenue fell from$743K to$405K , but that did not materially change how the company runs because sales are too small to carry the cost base. Operating cash burn still sat near$8.9M and was effectively replaced by financing inflows of$9.6M , which means outside capital, not commercialization, is currently what keeps the research engine moving.
The expense base is R&D-led: FY2025 research and development was
The balance sheet is not debt-heavy, with total liabilities of
Financial Health Signals
Can-Fite BioPharma Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Can-Fite BioPharma Ltd. scores -27.32, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($7.7M) relative to total liabilities ($3.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Can-Fite BioPharma Ltd. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Can-Fite BioPharma Ltd. reported a net loss of $9.8M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Can-Fite BioPharma Ltd. reported an operating loss of $9.9M against $284K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Can-Fite BioPharma Ltd. generated $405K in revenue in fiscal year 2025. This represents a decrease of 39.9% from the prior year.
Can-Fite BioPharma Ltd.'s EBITDA was -$9.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 22.2% from the prior year.
Can-Fite BioPharma Ltd. reported -$9.8M in net income in fiscal year 2025. This represents a decrease of 24.7% from the prior year.
Can-Fite BioPharma Ltd. earned -$5.97 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Can-Fite BioPharma Ltd. recorded an outflow of $9.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 17.1% from the prior year.
Can-Fite BioPharma Ltd. held $5.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Can-Fite BioPharma Ltd.'s ROE was -175.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 30.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Can-Fite BioPharma Ltd. invested $6.7M in research and development in fiscal year 2025. This represents an increase of 16.3% from the prior year.
Can-Fite BioPharma Ltd. invested $2K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 60.0% from the prior year.
Not reported for fiscal year 2025.
CANF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $405K-39.9% | $674K-9.3% | $743K-8.3% | $810K-5.0% | $853K+11.8% | $763K-62.5% | $2.0M-46.8% | $3.8M+384.2% | $789K | N/A | N/A |
| R&D Expenses | $6.7M+16.3% | $5.8M-3.8% | $6.0M-22.9% | $7.8M-21.2% | $9.8M-17.6% | $12.0M+8.9% | $11.0M+80.7% | $6.1M+19.0% | $5.1M-16.5% | $6.1M+56.6% | $3.9M |
| SG&A Expenses | $3.7M+20.2% | $3.0M+3.1% | $3.0M+1023.6% | $263K-43.6% | $466K+47.0% | $317K-89.7% | $3.1M-3.0% | $3.2M+10.1% | $2.9M+4.9% | $2.7M-0.1% | $2.7M |
| Operating Income | -$9.9M-22.4% | -$8.1M+0.8% | -$8.2M+18.8% | -$10.1M+21.4% | -$12.8M+9.2% | -$14.1M-17.8% | -$12.0M-121.8% | -$5.4M+24.6% | -$7.2M | N/A | N/A |
| Interest Expense | $284K-2.4% | $291K-42.5% | $506K+327.9% | -$222K-197.8% | $227K+174.7% | -$304K+50.8% | -$618K+46.4% | -$1.2M | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $4K-86.2% | $29K | N/A | N/A |
| Net Income | -$9.8M-24.7% | -$7.9M-3.2% | -$7.6M+25.0% | -$10.2M+19.4% | -$12.6M+12.7% | -$14.4M-14.4% | -$12.6M-92.1% | -$6.6M-35.7% | -$4.8M+42.3% | -$8.4M-28.9% | -$6.5M |
| EPS (Diluted) | -$5.97 | -$10.86 | -$17.92 | -$0.01 | -$0.03+25.0% | -$0.04 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
CANF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.5M+4.3% | $9.1M-8.7% | $10.0M+7.6% | $9.3M-54.2% | $20.3M+112.7% | $9.5M+16.5% | $8.2M+2.8% | $8.0M | N/A | N/A | N/A |
| Current Assets | $9.4M+5.1% | $9.0M-9.3% | $9.9M+8.2% | $9.2M-54.4% | $20.1M+113.5% | $9.4M+31.6% | $7.1M-9.6% | $7.9M | N/A | N/A | N/A |
| Cash & Equivalents | $5.5M+14.6% | $4.8M+12.8% | $4.3M+43.7% | $3.0M-32.2% | $4.4M-46.9% | $8.3M+206.6% | $2.7M-25.4% | $3.6M+3.1% | $3.5M-56.8% | $8.1M | N/A |
| Accounts Receivable | N/A | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.9M+6.5% | $3.7M-1.7% | $3.7M-22.1% | $4.8M-18.1% | $5.9M+70.2% | $3.4M-39.8% | $5.7M+16.1% | $4.9M | N/A | N/A | N/A |
| Current Liabilities | $2.7M+33.1% | $2.1M+1.6% | $2.0M-19.3% | $2.5M-8.4% | $2.7M+115.1% | $1.3M-61.2% | $3.3M+4.9% | $3.1M | N/A | N/A | N/A |
| Total Equity | $5.6M+2.9% | $5.4M-12.9% | $6.2M+39.6% | $4.5M-68.9% | $14.4M+136.8% | $6.1M+148.7% | $2.4M-19.0% | $3.0M+1.0% | $3.0M-23.6% | $3.9M | N/A |
| Retained Earnings | -$176.2M-5.9% | -$166.4M-5.0% | -$158.5M-5.1% | -$150.8M-7.2% | -$140.7M-12.1% | -$125.5M-13.7% | -$110.3M-12.9% | -$97.7M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
CANF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.9M-17.2% | -$7.6M+9.5% | -$8.4M+21.9% | -$10.8M-9.6% | -$9.9M+18.3% | -$12.1M-8.8% | -$11.1M-166.8% | -$4.2M+53.7% | -$9.0M | N/A | N/A |
| Capital Expenditures | $2K-60.0% | $5K+150.0% | $2K-77.8% | $9K-18.2% | $11K-57.7% | $26K+766.7% | $3K-90.9% | $33K+371.4% | $7K | N/A | N/A |
| Free Cash Flow | -$9.0M-17.1% | -$7.6M+9.5% | -$8.4M+21.9% | -$10.8M-9.5% | -$9.9M+18.4% | -$12.1M-9.0% | -$11.1M-164.7% | -$4.2M+53.4% | -$9.0M | N/A | N/A |
| Investing Cash Flow | -$2K-100.1% | $1.5M+200.2% | $498K-94.8% | $9.5M+165.5% | -$14.5M-55711.5% | -$26K-766.7% | -$3K+90.9% | -$33K-13.8% | -$29K | N/A | N/A |
| Financing Cash Flow | $9.6M+43.7% | $6.7M-26.6% | $9.1M | N/A | $20.5M+15.7% | $17.7M+73.9% | $10.2M+131.8% | $4.4M-1.9% | $4.5M | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | $2.6M+262.2% | $715K | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
CANF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -2456.8% | -1206.2% | -1103.0% | -1246.4% | -1505.5% | -1853.1% | -590.9% | -141.7% | -910.7% | N/A | N/A |
| Net Margin | -2426.7% | -1169.1% | -1027.5% | -1255.9% | -1478.9% | -1892.9% | -621.3% | -172.0% | -613.7% | N/A | N/A |
| Return on Equity | -175.8%-30.8pp | -145.0%-22.7pp | -122.3%+105.2pp | -227.5%-139.8pp | -87.7%+150.1pp | -237.8%+279.2pp | -517.0%-299.1pp | -217.9%-55.7pp | -162.3%+52.6pp | -214.8% | N/A |
| Return on Assets | -103.3%-16.9pp | -86.4%-10.0pp | -76.4%+33.2pp | -109.6%-47.3pp | -62.3%+89.4pp | -151.7%+2.8pp | -154.4%-71.8pp | -82.6% | N/A | N/A | N/A |
| Current Ratio | 3.46-0.9x | 4.38-0.5x | 4.91+1.2x | 3.66-3.7x | 7.35-0.1x | 7.41+5.2x | 2.18-0.3x | 2.53 | N/A | N/A | N/A |
| Debt-to-Equity | 0.700.0x | 0.68+0.1x | 0.60-0.5x | 1.08+0.7x | 0.41-0.2x | 0.57-1.8x | 2.35+0.7x | 1.64 | N/A | N/A | N/A |
| FCF Margin | -2210.1% | -1133.8% | -1136.2% | -1334.6% | -1157.0% | -1584.4% | -545.6% | -109.6% | -1138.0% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Can-Fite BioPharma Ltd. Ranks
Frequently Asked Questions
What is Can-Fite BioPharma Ltd.'s annual revenue?
Can-Fite BioPharma Ltd. (CANF) reported $405K in total revenue for fiscal year 2025. This represents a -39.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Can-Fite BioPharma Ltd.'s revenue growing?
Can-Fite BioPharma Ltd. (CANF) revenue declined by 39.9% year-over-year, from $674K to $405K in fiscal year 2025.
Is Can-Fite BioPharma Ltd. profitable?
No, Can-Fite BioPharma Ltd. (CANF) reported a net income of -$9.8M in fiscal year 2025.
What is Can-Fite BioPharma Ltd.'s EBITDA?
Can-Fite BioPharma Ltd. (CANF) had EBITDA of -$9.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Can-Fite BioPharma Ltd.'s return on equity (ROE)?
Can-Fite BioPharma Ltd. (CANF) has a return on equity of -175.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Can-Fite BioPharma Ltd.'s free cash flow?
Can-Fite BioPharma Ltd. (CANF) recorded an outflow of $9.0M in free cash flow during fiscal year 2025. This represents a -17.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Can-Fite BioPharma Ltd.'s operating cash flow?
Can-Fite BioPharma Ltd. (CANF) recorded an outflow of $8.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Can-Fite BioPharma Ltd.'s total assets?
Can-Fite BioPharma Ltd. (CANF) had $9.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Can-Fite BioPharma Ltd.'s capital expenditures?
Can-Fite BioPharma Ltd. (CANF) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Can-Fite BioPharma Ltd. spend on research and development?
Can-Fite BioPharma Ltd. (CANF) invested $6.7M in research and development during fiscal year 2025.
What is Can-Fite BioPharma Ltd.'s current ratio?
Can-Fite BioPharma Ltd. (CANF) had a current ratio of 3.46 as of fiscal year 2025, which is generally considered healthy.
What is Can-Fite BioPharma Ltd.'s debt-to-equity ratio?
Can-Fite BioPharma Ltd. (CANF) had a debt-to-equity ratio of 0.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Can-Fite BioPharma Ltd.'s return on assets (ROA)?
Can-Fite BioPharma Ltd. (CANF) had a return on assets of -103.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Can-Fite BioPharma Ltd.'s cash runway?
Based on fiscal year 2025 data, Can-Fite BioPharma Ltd. (CANF) had $5.5M in cash against an annual operating cash burn of $8.9M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Can-Fite BioPharma Ltd.'s Altman Z-Score?
Can-Fite BioPharma Ltd. (CANF) has an Altman Z-Score of -27.32, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Can-Fite BioPharma Ltd.'s Piotroski F-Score?
Can-Fite BioPharma Ltd. (CANF) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Can-Fite BioPharma Ltd.'s earnings high quality?
Can-Fite BioPharma Ltd. (CANF) reported a net loss of $9.8M while operations used $8.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Can-Fite BioPharma Ltd. cover its interest payments?
Can-Fite BioPharma Ltd. (CANF) reported an operating loss of $9.9M against $284K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.